Literature DB >> 3459704

Mononuclear cells in myopathies: quantitation of functionally distinct subsets, recognition of antigen-specific cell-mediated cytotoxicity in some diseases, and implications for the pathogenesis of the different inflammatory myopathies.

A G Engel, K Arahata.   

Abstract

Monoclonal antibodies reactive for B cells, T cells, T-cell subsets, killer (K) and natural killer (NK) cells, and the Ia antigen were used to analyze mononuclear cell subsets in scleroderma (SD), dermatomyositis (DM), polymyositis (PM), inclusion body myositis (IBM), Duchenne dystrophy (DD), and normal muscle. The analysis, which was quantitative, was performed according to diagnosis and site of accumulation. Cells at perivascular, perimysial, and endomysial sites of accumulation, and cells focally surrounding and invading nonnecrotic muscle fibers, were analyzed separately. Individual antigens were localized in 2-micron serial sections, or multiple antigens were demonstrated in a given section by sequential paired immunofluorescence. The latter approach allowed the identification of the cell phenotypes in which functional properties are defined by multiple markers, e.g., T8+ and T4+ cells that are either activated or not activated, T8+ cells that are either cytotoxic or suppressor T cells, and K/NK cells of varying maturity and killing capability. The interactions of inflammatory cells of various types with each other and the muscle fiber were further investigated by immunoelectron microscopy. In SD, the findings provide evidence for a cell-mediated immune effector response against a connective tissue and/or vascular element. In DM, the effector response appears to be predominantly humoral. In PM and IBM (but not in DM or SD), there is invasion and destruction of nonnecrotic muscle fibers by cytotoxic T cells, with or without accompanying macrophages. Because T-cell-mediated injury is antigen- and major histocompatibility complex-restricted, clones of T cells must have been sensitized previously to a muscle fiber-associated surface antigen. The identity of the putative antigen(s) remains an important, unsolved question.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3459704     DOI: 10.1016/s0046-8177(86)80180-0

Source DB:  PubMed          Journal:  Hum Pathol        ISSN: 0046-8177            Impact factor:   3.466


  53 in total

1.  Conditional up-regulation of MHC class I in skeletal muscle leads to self-sustaining autoimmune myositis and myositis-specific autoantibodies.

Authors:  K Nagaraju; N Raben; L Loeffler; T Parker; P J Rochon; E Lee; C Danning; R Wada; C Thompson; G Bahtiyar; J Craft; R Hooft Van Huijsduijnen; P Plotz
Journal:  Proc Natl Acad Sci U S A       Date:  2000-08-01       Impact factor: 11.205

Review 2.  The idiopathic inflammatory myopathies and their treatment.

Authors:  J Walton
Journal:  J Neurol Neurosurg Psychiatry       Date:  1991-04       Impact factor: 10.154

3.  Altered cytokine expression of peripheral blood lymphocytes in polymyositis and dermatomyositis.

Authors:  M Aleksza; A Szegedi; P Antal-Szalmás; B Irinyi; L Gergely; A Ponyi; J Hunyadi; S Sipka; M Zeher; G Szegedi; K Dankó
Journal:  Ann Rheum Dis       Date:  2005-04-13       Impact factor: 19.103

4.  The inflammatory milieu in idiopathic inflammatory myositis.

Authors:  Ann M Reed; Floranne Ernste
Journal:  Curr Rheumatol Rep       Date:  2009-08       Impact factor: 4.592

Review 5.  Immunotherapy of myositis: issues, concerns and future prospects.

Authors:  Marinos C Dalakas
Journal:  Nat Rev Rheumatol       Date:  2010-02-02       Impact factor: 20.543

6.  Skeletal muscle expression of class II histocompatibility antigens (HLA-DR) in polymyositis and other muscle disorders with an inflammatory infiltrate.

Authors:  J A Zuk; A Fletcher
Journal:  J Clin Pathol       Date:  1988-04       Impact factor: 3.411

7.  Sarcolemmal Complement Membrane Attack Complex Deposits During Acute Rejection of Myofibers in Nonhuman Primates.

Authors:  Daniel Skuk; Jacques P Tremblay
Journal:  J Neuropathol Exp Neurol       Date:  2019-01-01       Impact factor: 3.685

Review 8.  Pharmacologic management of Duchenne muscular dystrophy: target identification and preclinical trials.

Authors:  Joe N Kornegay; Christopher F Spurney; Peter P Nghiem; Candice L Brinkmeyer-Langford; Eric P Hoffman; Kanneboyina Nagaraju
Journal:  ILAR J       Date:  2014

Review 9.  Immune-mediated mechanisms potentially regulate the disease time-course of duchenne muscular dystrophy and provide targets for therapeutic intervention.

Authors:  Nicholas P Evans; Sarah A Misyak; John L Robertson; Josep Bassaganya-Riera; Robert W Grange
Journal:  PM R       Date:  2009-08       Impact factor: 2.298

10.  Differential immunohistological features of inflammatory myopathies and dysferlinopathy.

Authors:  Jae-Hwan Choi; Yeong-Eun Park; Sung-Il Kim; Jeong-Il Kim; Chang-Hoon Lee; Kyu-Hyun Park; Dae-Seong Kim
Journal:  J Korean Med Sci       Date:  2009-11-07       Impact factor: 2.153

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.